A recent study has shown that simultaneous addition of Src inhibitors with paclitaxel may not be ideal for cancer control; however, sequential addition of Src inhibitor after paclitaxel treatment may overcome the adaptive paclitaxel-induced chemoresistance changes making resistant cells sensitive to dual therapy [46]. Here, SRC is linked to cancer.